Research & Development in Singapore
The Observational & Pragmatic Research Institute Pte Ltd (OPRI) is an independent research institute uniquely placed to deliver advances in research and development in Singapore and globally. OPRI strives to improve the lives of patients through global research and the translation of novel innovations into direct patient impact.
OPRI was incorporated in Singapore on 7th February 2014, underpinned by the investment of its longstanding affiliate research unit within the United Kingdom (Observational and Pragmatic Research International Ltd), which was incorporated over 18 years ago on 26th April 2001.
The funded research delivered by OPRI facilitates OPRI’s continued investment into novel research and development programs within Singapore and across the world. The Institute aims to become a flagship R&D facility within Singapore, adding tremendous value to the substantial investment already made in the infrastructure of OPRI’s existing Singapore business.
Severe Asthma Projects
OPRI’s “Severe or Uncontrolled Asthma” project, which is one phase of R&D in the research journey, aims to undertake research studies to first uncover new knowledge on Severe Asthma (SA) and its related issues. The acquired new knowledge from this phase of R&D can then lead to further generation of new knowledge and the development of new treatment methodologies/ biologics.
The new knowledge from each research topic of the OPRI R&D project is streamlined accumulatively into a digital health tool/ registry to facilitate easier access by medical professionals in Singapore and around the world to more effectively treat severe asthma whilst the development of new treatment methodologies/biologics can be concurrently undertaken from the new knowledge gained.
For example, the new knowledge generated from these projects has resulted in the development of a first of its kind Singapore Severe Asthma Registry (SSAR). The SSAR will be the first multi-centre, large-scale registry of severe asthma patients in Singapore which also will be part of the International Severe Asthma Registry (ISAR), the first global partnership of researchers from 26 countries.